全文获取类型
收费全文 | 31002篇 |
免费 | 2590篇 |
国内免费 | 1758篇 |
专业分类
耳鼻咽喉 | 29篇 |
儿科学 | 524篇 |
妇产科学 | 149篇 |
基础医学 | 4506篇 |
口腔科学 | 94篇 |
临床医学 | 2722篇 |
内科学 | 12923篇 |
皮肤病学 | 149篇 |
神经病学 | 250篇 |
特种医学 | 544篇 |
外国民族医学 | 4篇 |
外科学 | 1014篇 |
综合类 | 5825篇 |
现状与发展 | 11篇 |
预防医学 | 2402篇 |
眼科学 | 30篇 |
药学 | 2317篇 |
11篇 | |
中国医学 | 1320篇 |
肿瘤学 | 526篇 |
出版年
2024年 | 26篇 |
2023年 | 378篇 |
2022年 | 461篇 |
2021年 | 875篇 |
2020年 | 913篇 |
2019年 | 1013篇 |
2018年 | 917篇 |
2017年 | 1012篇 |
2016年 | 1226篇 |
2015年 | 1260篇 |
2014年 | 1965篇 |
2013年 | 2093篇 |
2012年 | 1873篇 |
2011年 | 2247篇 |
2010年 | 1694篇 |
2009年 | 1542篇 |
2008年 | 1564篇 |
2007年 | 1678篇 |
2006年 | 1625篇 |
2005年 | 1326篇 |
2004年 | 1141篇 |
2003年 | 1042篇 |
2002年 | 901篇 |
2001年 | 932篇 |
2000年 | 765篇 |
1999年 | 615篇 |
1998年 | 518篇 |
1997年 | 495篇 |
1996年 | 438篇 |
1995年 | 444篇 |
1994年 | 380篇 |
1993年 | 314篇 |
1992年 | 275篇 |
1991年 | 211篇 |
1990年 | 169篇 |
1989年 | 140篇 |
1988年 | 145篇 |
1987年 | 116篇 |
1986年 | 93篇 |
1985年 | 102篇 |
1984年 | 85篇 |
1983年 | 51篇 |
1982年 | 60篇 |
1981年 | 50篇 |
1980年 | 50篇 |
1979年 | 33篇 |
1978年 | 38篇 |
1977年 | 23篇 |
1976年 | 9篇 |
1973年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
21.
Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C 下载免费PDF全文
Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Hideyuki Nomura Akira Kawano Kazuhiro Takahashi Kazufumi Dohmen Takeaki Satoh Koichi Azuma Makoto Nakamuta Toshimasa Koyanagi Kazuhiro Kotoh Shinji Shimoda Jun Hayashi The Kyushu University Liver Disease Study Group 《Journal of gastroenterology and hepatology》2015,30(8):1309-1316
22.
S. Nishida J. J. Gaynor N. Nakamura F. Butt H. G. Illanes J. Kadono G. W. Neff D. M. Levi J. I. Moon G. Selvaggi T. Kato P. Ruiz A. G. Tzakis J. R. Madariaga 《American journal of transplantation》2006,6(1):140-149
A retrospective study of 1058 liver transplant recipients was performed to determine: (i) the incidence, etiology, timing, clinical features and treatment of refractory ascites (RA), (ii) risk factors for RA development, (iii) predictors of RA disappearance, (iv) predictors of survival following RA and (v) the impact of RA on patient survival. Sixty-two patients (5.9%) developed RA and its disappearance occurred in 27/62 cases. Patients having hepatitis C virus (HCV) had a significantly higher hazard rate of developing RA (p < 0.00001). No other baseline characteristic was associated with RA. Cox stepwise regression analysis of the hazard rate of RA disappearance found two significant factors: HCV recurrence as the reason for developing RA implied a poorer outcome (p = 0.006), whereas an unknown reason implied a favorable outcome (p = 0.02). In addition, survival following RA was significantly poorer among patients having bacterial peritonitis or HCV recurrence. Finally, the mortality rate was significantly (nearly 8.6 times) higher in patients following RA development while it was ongoing (p < 0.00001); however, if the RA disappeared, then the additional risk of death also disappeared. This study illustrates the importance of developing an optimal treatment strategy to (i) effectively treat RA if it develops and (ii) prevent hepatitis C recurrence. 相似文献
23.
Marieke C Wichers Gunter Kenis Carsten Leue Ger Koek Geert Robaeys Michael Maes 《Neuropsychopharmacology》2006,60(1):77-79
BACKGROUND: Major depression has been associated cross-sectionally with increased cell-mediated immune activation but causality has been difficult to establish. This study prospectively investigated the hypothesis that baseline level of immune activation predicts the development of depression during interferon-alpha (IFN-alpha) treatment. METHODS: Sixteen hepatitis C patients without psychiatric disorder underwent IFN-alpha treatment. Proinflammatory and anti-inflammatory cytokines were determined before starting treatment. Presence of a major depressive disorder (MDD) was assessed at baseline and several times during treatment. RESULTS: Baseline soluble interleukin-2 receptor (sIL-2r), interleukin-6 (IL-6), and interleukin-10 (IL-10) concentrations were significantly increased in the five subjects that developed MDD during treatment compared with those that did not, with standardized effect sizes of 1.08, 1.16, and 1.25, respectively, controlling for marijuana use, cigarette smoking, and baseline level of depressive symptoms. CONCLUSIONS: Results suggest that increased immune activation, rather than an epiphenomenon, is a causal risk factor for the development of MDD. 相似文献
24.
Dino Donataccio Francine Roggen Chantal De Reyck Catherine Verbaandert Monique Bodeus Jan Lerut 《Transplant international》2006,19(1):38-43
The use of livers from anti-hepatitis B core (HBc) positive donors can alleviate donor shortage. Nineteen of 367 (6%) adults receiving anti-HBc positive allografts [three were hepatitis B antigen (HBsAg) negative, hepatitis B antibody (HBsAb) positive; four were HBsAg positive and 12 were not exposed to hepatitis B viral (HBV) infection] were retrospectively reviewed. In HBsAg negative recipients, immunoprophylaxis (IP) was guided by viral serology and immunohistochemistry (IH) of day 0 and day 7 liver biopsies. If IH was negative, IP was stopped. None of three HBsAg negative, HBsAb positive recipients infected; one (replicating) of four HBsAg positive recipients reinfected and seven of eight (87.5%) HBsAg, HBsAb negative recipients, who did not receive long-term IP, infected after a median time of 2 years (range 1-5); one patient died of liver failure. Four HBsAg, HBsAb negative recipients, receiving life-long IP, remained infection free. Anti-HBc positive donor livers must be directed selectively first to HBsAg positive recipients, next to recipients having HBV antibodies and finally to HBV-naive recipients. Identification of both donor and recipient risk factors for HBV infection before transplantation allows indiscriminate use of antiviral prophylaxis. The necessity for IP therapy should be guided by HBV-DNA testing of donor liver tissue and serum. IH of early liver biopsies is an unreliable marker for predicting antiviral treatment requirements. 相似文献
25.
凯时治疗慢性重型肝炎患者疗效观察 总被引:2,自引:0,他引:2
目的探讨凯时即前列地尔脂微球载体制剂(Lipo-PGE1)治疗慢性重型肝炎的疗效。方法将84例慢性重型肝炎患者随机分成两组,对照组予综合治疗及对症治疗,治疗组在该基础上加用凯时10μg溶于5%葡萄糖注射液250ml中静脉缓慢滴注,1次/d,疗程为4周。结果治疗组对慢性重型肝炎的疗效优于对照组(P〈0.01),肝功能改善优于对照组(P〈0.01)。结论Lipo-PCEI是一种治疗慢性重型肝炎安全、有效的药物。 相似文献
26.
AIM/BACKGROUND: Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of unknown aetiology. Up to 10% of patients with typical features of PBC will have additional features of autoimmune hepatitis (AIH). A subset, however, have no such features but go on to develop a 'sequential' AIH overlap syndrome. Objectives: Describe our experience with eight patients who developed AIH after the diagnosis of PBC was made. METHODS: We reviewed the charts of all PBC patients over a 9-year period (from 1996 to 2005). Only PBC patients with no features of AIH were included. RESULTS: There were 1476 patients with PBC. Of these, eight patients developed features of AIH overlap syndrome based on biochemical and histological parameters. Treatment included prednisone and azathioprine for 24 or more months. The majority of patients remained on ursodeoxycholic acid (UDCA) throughout treatment. Response to therapy was defined by improvement in enzymes, and was rapid for all patients. One patient was able to discontinue treatment with prednisone and azathioprine, while seven have continued on therapy to date. CONCLUSIONS: A 'sequential' overlap syndrome of AIH with PBC can occur. Treatment with prednisone and azathioprine may lead to a rapid improvement in aminotransferase levels. 相似文献
27.
目的 研究乙型肝炎病毒(HBV)自身增强子I(enhancerI,ENHI)对HBV DNA疫苗免疫应答的影响。方法 采用PCR法以HBVadr亚型全基因DNA序列为模板分别扩增表面抗原(HBsAg)和HBsA-ENHI基因片段,重组到载体VR1012中,构建两种HBV DNA疫苗,转染CADS-7细胞及HepG2细胞并免疫BALB/c小鼠。采用蛋白印迹、ELISA、ELISPOT等方法检测其在COS-7和HepG2细胞内的表达及小鼠的体液及细胞免疫应答效果。结果 转染的HepG2和COS-7细胞均表达HBsAg;连接ENHI的HBV DNA疫苗转染HepG2细胞后HBsAg表达量明显升高,两种疫苗转染COS-7细胞表达HBsAg无明显差异;免疫小鼠后第2周产生HBsAb及HBsAg特异性细胞毒T淋巴细胞(CTL),两种疫苗免疫产生的HBsAb及HBsAg特异性CTL无明显差异。结论ENHI可使HBV DNA疫苗转染HepG2细胞表达HBsAg明显增加,对转染COS-7细胞表达HBsAg及接种BALB/C小鼠引起的免疫应答无明显影响。 相似文献
28.
申秀敏 《中国医学检验杂志》2006,7(6):420-421
[目的]探讨各型肝炎的感染率。[方法]研究对象为我院住院及门诊患者,共计4110例。采用微粒子酶免分析法(MEIA)及酶联免疫吸附法(ELISA)进行肝炎分型(甲、乙、丙、丁、戊、庚肝)检测。[结果]4110例受检者中,单纯乙肝感染者133例,占3.24%;单纯丙肝感染者134例,占3.26%;单纯戊肝感染者2例,占0.05%;乙肝合并丙肝感染者3例,占0.07%;丙肝合并戊肝感染者1例,占0.02%;HAV、HDV、HGV无一例感染,感染率为0。另外,男性受检者2088人,乙肝感染者88人,占4.21%;丙肝感染者48人,占2.30%;女性受检者2022人,乙肝感染45人,占2.23%;丙肝感染86人,占4.25%。[结论]除丙肝外,各型感染率均低于全国平均感染率,与相关资料报道相差甚远。乙肝及丙肝仍以单纯感染多见。另,本组资料还显示,男性较女性更易感染乙肝病毒,而女性感染丙肝者远远高于男性,对于丙肝感染的性别差异,尚无报道,需进一步探讨。 相似文献
29.
Hepatitis C virus (HCV) infection is a major health care issue in liver and kidney transplantation. Besides negatively affecting both patient and graft survival, HCV is associated with a heightened risk for new onset diabetes mellitus (NODM). The mechanisms underlying the diabetogenicity of HCV are complex but are likely to involve insulin resistance caused by inhibitory actions of the virus on insulin regulatory pathways in the liver. The resultant glucose dysregulation is an important determinant of increased morbidity and mortality in liver and kidney recipients. This review highlights the concerns for outcomes in HCV-positive liver and kidney transplant patients with particular focus on the interrelationship between hepatitis C and diabetes. Data about the potential role of calcineurin inhibitors, corticosteroids and mycophenolate mofetil in HCV infection and HCV-associated NODM will also be discussed. 相似文献
30.